Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
ConclusionsClinicians providing care for patients receiving moxetumomab pasudotox-tdfk should be aware of the strategies required for safe administration, including the management of serious adverse events.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Drugs & Pharmacology | Hairy Cell Leukemia | Headache | Hemolytic Uremic Syndrome (HUS) | Leukemia | Migraine | Toxicology